刘新兰_宁夏医科大学机构知识库

检索banner

刘新兰分享到

研究方向：

学科领域：

成果数量：

147

CSCD收录:

北大核心收录:

超星被引量：

322

WOS被引量：

H指数：

G指数：

检索结果：返回 147 结果。

排序：

期刊

HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study CPCI-S

作者： Huai-liang Wu ， Wen Xia ， Zhengyang Xu ， Hanxing Zhou ， Limin Chen ， Yongkui Lu ， Xinlan Liu ， Danmei Pang ， Yan Liu ， Qianyi Lu ， Fei Xu ， Xin An ， Jiajia Huang ， Kuikui Jiang ， Jingmin Zhang ， Yili Cai ， Ruoxi Hong ， Qiufan Zheng ， null ， Shusen Wang （ ¹Department of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China;²Chemoradiotherapy Center of Oncology, The affiliated people’s hospital of Ningbo University, Ningbo, China;³Department of Medical Oncology, The affiliated seventh hospital of Sun Yat-sen University, Shenzhen, China;⁴Department of Breast, Bone & Soft Tissue Oncology, Guangxi Medical University Cancer Hospital, Nanning, China;⁵Department of Oncology, Ningxia Medical University General Hospital, Yinchuan, China;⁶Department of Breast Oncology, The First People’s Hospital of Foshan, Foshan, China ）
出处： Signal Transduction and Targeted Therapy 2026 Vol.11
摘要： Treatment options for patients with hormone receptor -positive, human epidermal growth factor receptor 2 -negative advanced breast cancer that progre

科技成果

RASSF6通过内质网应激-线粒体凋亡途径提高胃癌细胞对奥沙利铂化疗敏感性作用及其机制研究

作者：厚玉瑾，刘新兰，王金，赵艳姣，张海霞，田稼，郭婷，王南，孙海涛
关键词：奥沙利铂化疗线粒体凋亡内质网应激化疗敏感性胃癌细胞
摘要：课题组早期研究中发现RASSF6基因和蛋白在胃癌细胞中低表达,且低表达与胃癌分化程度、肿瘤浸润深度、淋巴结转移、胃癌分期有关。RASSF6过表达可抑制胃癌细胞增殖、迁移,促进凋亡。本研究认为RASSF6表达可抑制细胞增殖且促进凋亡,相关机制如下：RASSF6抑制MAPK通路及AKT信号途径,从而抑制

期刊

Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer:the phase 2 NeoSAC trial

作者： Guoshuang Shen ， Zhilin Liu ， Miaozhou Wang ， Yi Zhao ， Xinlan Liu ， Yujin Hou ， Wenbiao Ma ， Jingqi Han ， Xiaofeng Zhou ， Dengfeng Ren ， Fuxing Zhao ， Zitao Li ， Shifen Huang ， Yongzhi Chen ， Yingjian He ， Yan Liu ， Zij （ Breast Disease Diagnosis and Treatment Center,Affiliated Hospital of Qinghai University,Affiliated Cancer Hospital of Qinghai University,Xining,China；Medical Oncology Department of General Hospital of Ningxia Medical University,Yinchuan,China;( ）
出处：信号转导与靶向治疗（英文版) 2025 第10卷第3期 P1578-1586
摘要： We aimed to evaluate the efficacy and safety of adding apatinib,to sintilimab and chemotherapy in the neoadjuvant treatment of early triple-negative b

期刊

Inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: a prospective, single-arm, phase 2 study CPCI-S

作者： Huimin Lv ， Tao Sun ， Xiaoling Ling ， Xinlan Liu ， Jin Yang ， Mengwei Zhang ， Limin Niu ， Shumin Chen ， Zhenzhen Liu ， Chengzheng Wang ， Huihui Sun ， Jing Wang ， Huiai Zeng ， Shengnan Zhao ， Lanwei Guo ， Yajing Feng ， Zhiqing Zhang ， Qingxin Xia ， Rongguo Qiu & …Min Yan （ ¹Department of Breast Disease, Henan Breast Cancer Center, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China;²Breast Medicine, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, Liaoning, China;³The First Hospital of Lanzhou University, Lanzhou, China;⁴Departments of Oncology, General Hospital of Ningxia Medical University, Yinchuan, China;⁵Department of Medical Oncology, the First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China;⁶Department of Clinical Research Management, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China;⁷Department of Pathology, the Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China;⁸Beijing Biostar Pharmaceuticals Co., Ltd., Beijing, China ）
出处： BMC Medicine 2026 Vol.24 No.1
关键词： Anti-HER2 therapy Immune checkpoint inhibitors Chemotherapy HER2-positive Advanced breast cancer
摘要： Background The efficacy and safety of anti-HER2 therapy and immune checkpoint inhibitors combined with chemotherapy to treat HER2-positive advanced b

期刊

Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer:the phase 2 NeoSAC trial

作者： Shen Guoshuang ， Liu Zhilin ， Wang Miaozhou ， Zhao Yi ， Liu Xinlan ， Hou Yujin ， Ma Wenbiao ， Han Jingqi ， Zhou Xiaofeng ， Ren Dengfeng ， Zhao Fuxing ， Li Zitao ， Huang Shifen ， Chen Yongzhi ， He Yingjian ， Liu Yan ， Zhu Zijun ， Li Yongxin ， Li Jinming ， Da Mengting ， Mo Hongnan ， Du Feng ， Cui Liang ， Bai Jing ， Liu Zhen ， Ma Fei ， Zhao Jiuda （ Affiliated Hospital of Qinghai University；Medical Oncology Department of General Hospital of Ningxia Medical University；Peking University Cancer Hospital & Institute；Medical College of Qinghai University；National Cancer Center/Cancer Hospital；Peking University Cancer Hospital and Institute；Geneplus-Beijing Institute ）
出处：信号转导和靶向治疗 2025 第10卷第3期 P1578-1586
摘要： We aimed to evaluate the efficacy and safety of adding apatinib, to sintilimab and chemotherapy in the neoadjuvant treatment of early triple-negative

期刊

Age at initial diagnosis and prognosis of breast cancer:a nationwide multicenter retrospective study in China

作者： Huan Yang ， Qu-Chang Ouyang ， Min Yan ， Xiao-Jia Wang ， Xi-Chun Hu ， Ze-Fei Jiang ， Tao Huang ， Zhong-Sheng Tong ， Shu-Sen Wang ， Yong-Mei Yin ， Hui Li ， Run-Xiang Yang ， Hua-Wei Yang ， Yue-E Teng ， Tao Sun ， Li Cai ， Hong-Yuan Li ， Xue-Nong Ouyang ， Jian-Jun He ， Xin-Lan Liu ， Shun-E Yang ， Jin-Hu Fan ， Jia-Yu Wang ， You-Lin Qiao ， Bing-He Xu （ Department of Cancer Epidemiology，National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College，Beijing，China；Department of Breast Cancer Medical Oncology，Hunan Cancer Hospital，Changsha，China；Department of Breast Disease，Henan Breast Cancer Center，The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital，Zhengzhou，China；Department of Medical Oncology，Zhejiang Cancer Hospital，Hangzhou，China；Department of Medical Oncology，Fudan University Shanghai Cancer Center，Shanghai，China；Department of Breast Cancer，The Fifth Medical Center of Chinese People’s Liberation Army General Hospital，Beijing，China；Department of Breast and Thyroid Surgery，Union Hospital，Tongji Medical College，Huazhong University of Science and Technology，Wuhan，China；Department of Breast Oncology，Key Laboratory of Breast Cancer Prevention and Therapy，National Clinical Research Center for Cancer，Tianjin Medical University Cancer Institute and Hospital，Tianjin，China；Department of Medical Oncology，State Key Laboratory of Oncology in South China，Sun Yat-sen University Cancer Center，Guangzhou，China；Department of Medical Oncology，The First Affiliated Hospital of Nanjing Medical University，Nanjing，China；Department of Breast Surgery，Sichuan Province Tumor Hospital，Chengdu，China；Department of Medical Oncology，Yunnan Cancer Hospital，Kunming Medical University，Kunming，China；Department of Breast Surgery，The Affiliated Tumor Hospital of Guangxi Medical University，Nanning，China；Departments of Medical Oncology and Thoracic Surgery，The First Hospital of China Medical University，Shenyang，China；Department of Medical Oncology，Cancer Hospital of China Medical University，Liaoning Cancer Hospital and Institute，Key Laboratory of Liaoning Breast Cancer Research，Shenyang，China；The Fourth Department of Internal Medical Oncology，Harbin Medical University Cancer Hospital，Harbin，China；Department of the Endocrine and Breast Surgery，The First Affiliated Hospital of Chongqing Medical University，Chongqing Medical University，Chongqing，China；Department of Medicine Oncology，900 Hospital of the Joint Logistics Team，Fuzhou，China；Department of Breast Surgery，The First Affiliated Hospital of Xi’an Jiaotong University，Xi’an，China；Department of Oncology，General Hospital of Ningxia Medical University，Yinchuan，China；Department of Breast Cancer and Lymphoma，Affiliated Tumor Hospital of Xinjiang Medical University，Urumqi，China；Department of Cancer Epidemiology，National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College，Beijing，China；Department of Medical Oncology，National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College，Beijing，China；Department of Cancer Epidemiology，National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College，Beijing，China；Department of Medical Oncology，National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College，Beijing，China ）
出处：转化医学年鉴 2022 第10卷第15期 P813
关键词： Age at initial diagnosis breast cancer clinicopathological characteristics treatment prognosis
摘要： Background Several studies have indicated possible associations between age and the prognosis of breast cancer , but limited data are available from h

期刊

Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: The Phase III MECCA Trial CPCI-S

作者： Hong, Ruo-Xi ， Xu, Fei ， Xia, Wen ， Teng, Yue-E ， Ouyang, Qu-Chang ， Zheng, Qiu-Fan ， Yuan, Zhong-Yu ， Chen, Dong-Shao ， Jiang, Kui-Kui ， Lin, Ying ， Dai, Zhen ， Liu, Xin-Lan ， Chen, Qian-Jun ， Wu, Xin-Hong ， Shi, Yan-Xia ， Huang, Jia-Jia ， An, Xin ， Xue, Cong ， Bi, Xi-Wen ， Chen, Mei-Ting ， Li, Hui ， Yao, He-Rui ， Zou, Guo-Rong ， Huang, Heng ， Zhang, Jing-Min ， Wang, Shu-Sen （ ^aDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China;^bDepartment of Breast Internal Medicine, The First Hospital of China Medical University, Shenyang, China;^cDepartment of Breast Cancer Medical Oncology, Hunan Cancer Hospital, Changsha, China;^dBreast Disease Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China;^eChengdu Center for Disease Control and Prevention, Chengdu, China;^fDepartment of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, China;^gDepartment of Breast, Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China;^hDepartment of Breast Cancer, Hubei Cancer Hospital, Wuhan, China;ⁱDepartment of Breast Surgery, Sichuan Cancer Hospital, Chengdu, China;^jBreast Tumor Centre, Department of Medical Oncology, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China;^kDepartment of Oncology, Panyu District Cancer Institute, Panyu Central Hospital, Guangzhou, China;^lDepartment of Breast Surgery, Lianjiang People’s Hospital, Lianjiang, China ）
出处： Journal of Clinical Oncology 2025 Vol.43 No.11 P1314-1324
摘要： PURPOSE The effects of metronomic chemotherapy plus endocrine therapy have yet to be elucidated through a randomized phase III clinical trial. METHODS

期刊

Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial CPCI-S

作者： Binghe Xu ， Qingyuan Zhang ， Yang Luo ， Zhongsheng Tong ， Tao Sun ， Changping Shan ， Xinlan Liu ， Yumin Yao ， Bing Zhao ， Shusen Wang ， Xiaohua Zeng ， Changlu Hu ， Xi Yan ， Xiaojia Wang ， Hongyan Jia ， Zhendong Chen ， Fuming Qiu ， Xinhong Wu ， Deyong Zhang ， null ， Tong Li （ ¹National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China;²Harbin Medical University Cancer Hospital, Harbin, China;³Tianjin Medical University Cancer Institute and Hospital, Tianjin, China;⁴Cancer Hospital of China Medical University, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital and Institute, Shenyang, China;⁵The Affiliated Hospital of Jining Medical University, Jining, China;⁶General Hospital of Ningxia Medical University, Yinchuan, China;⁷Liaocheng People’s Hospital, Liaocheng, China;⁸Cancer Hospital of Xinjiang Medical University, Urumuqi, China;⁹Sun Yat-sen University Cancer Center, Guangzhou, China;¹⁰Breast Cancer Center, Affiliated Cancer Hospital of Chongqing University, Chongqing, China;¹¹Anhui Provincial Cancer Hospital, Hefei, China;¹²West China Hospital, Sichuan University, Chengdu, China;¹³Cancer Hospital of the University of Chinese Academy of Sciences/Zhejiang Cancer Hospital, Institute of Cancer and Basic Medicine, Chinese Academy of Sciences, Hangzhou, China;¹⁴The First Hospital of Shanxi Medical University, Taiyuan, China;¹⁵The Second Affiliated Hospital of Anhui Medical University, Hefei, China;¹⁶The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China;¹⁷Hubei Cancer Hospital, Wuhan, China;¹⁸Genor Biopharma Co., Ltd, Beijing, China ）
出处： Nature Communications 2025 Vol.16
摘要： Lerociclib , a highly selective oral CDK4/6 inhibitor, has displayed anti-tumor activity and differentiated safety and tolerability profile in previou

期刊

Nomogram for predicting the risk and prognosis of lung metastasis of four subtypes of breast cancer:A population-based study from SEER

作者： Yuanfang Xin ， Guoxin Zhang ， Qiuxia Dong ， Yaobang Liu ， Xingfa Huo ， Yumei Guan ， Yonghui Zheng ， Qianqian Fang ， Dengfeng Ren ， Fuxing Zhao ， Zitao Li ， Xinlan Liu ， Jiuda Zhao （ Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University，Xining，Qinghai 810000，China；The Second Ward of Oncology，Qinghai Red Cross Hospital，Xining，Qinghai 810000，China；Department of Medical Oncology，General Hospital of Ningxia Medical University，Yinchuan，Ningxia 750000，China；The Second Ward of Oncology，Qinghai Red Cross Hospital，Xining，Qinghai 810000，China；Department of Surgical Oncology，General Hospital of Ningxia Medical University，Yinchuan，Ningxia 750000，China；Precision Medicine Center of Oncology，The Affiliated Hospital of Qingdao University，Qingdao，Shandong 266035，China；Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University，Xining，Qinghai 810000，China；Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University，Xining，Qinghai 810000，China；Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University，Xining，Qinghai 810000，China；Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University，Xining，Qinghai 810000，China；Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University，Xining，Qinghai 810000，China；Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University，Xining，Qinghai 810000，China；Department of Medical Oncology，General Hospital of Ningxia Medical University，Yinchuan，Ningxia 750000，China；Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University，Xining，Qinghai 810000，China ）
出处：癌症发生与治疗(英文) 2025 第3卷第2期 P154-162
关键词： Breast cancer Lung metastasis Nomogram Prognosis Surveillance Survival prediction model
摘要： Background: Breast cancer is the most diagnosed cancer worldwide, and patients' survival decreases with metastasis. We conducted a retrospective stud

期刊

Neoadjuvant apatinib addition to sintilimab and carboplatin-taxane based chemotherapy in patients with early triple-negative breast cancer: the phase 2 NeoSAC trial CPCI-S

作者： Guoshuang Shen ， Zhilin Liu ， Miaozhou Wang ， Yi Zhao ， Xinlan Liu ， Yujin Hou ， Wenbiao Ma ， Jingqi Han ， Xiaofeng Zhou ， Dengfeng Ren ， Fuxing Zhao ， Zitao Li ， Shifen Huang ， Yongzhi Chen ， Yingjian He ， Yan Liu ， Zijun Zhu ， Yongxin Li ， Jinming Li ， Mengting Da ， Hongnan Mo ， Feng Du ， Liang Cui ， Jing Bai ， Zhen Liu ， Fei Ma ， Jiuda Zhao （ ¹Breast Disease Diagnosis and Treatment Center, Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University;²Medical Oncology Department of General Hospital of Ningxia Medical University;³Department of Oncology, 2nd Ward, Qinghai Provincial People’s Hospital (Breast and Thyroid Surgery);⁴Department of pathology, Affiliated Hospital of Qinghai University, Affiliated Cancer Hospital of Qinghai University;⁵Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Breast Center, Peking University Cancer Hospital & Institute;⁶Department of Public Health, Medical College of Qinghai University;⁷State Key Laboratory of Molecular Oncology, Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College;⁸Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing),The VIPII Gastrointestinal Cancer Division of Medical Department, Peking University Cancer Hospital and Institute, 52 Fucheng Rd, Haidian District;⁹Geneplus-Beijing Institute ）
出处： Signal Transduction and Targeted Therapy 2025 Vol.10 No.1 P1-9
摘要： We aimed to evaluate the efficacy and safety of adding apatinib, to sintilimab and chemotherapy in the neoadjuvant treatment of early triple-negative

共147条记录 1/15 第一页 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] 下一页最后一页到第页